摘要
目的分析乙型肝炎表面抗原(HBs Ag)阴性的非霍奇金淋巴瘤(NHL)患者化疗后乙型肝炎病毒(HBV)再激活的影响因素。方法选取112例NHL患者,按照随机数字表法分为观察组和对照组,每组56例。所有患者均给予环磷酰胺+多柔比星+长春新碱+醋酸泼尼松(CHOP)或利妥昔单抗+CHOP(R-CHOP)化疗方案,观察组患者于化疗前1周开始口服恩替卡韦。比较两组患者的HBV再激活率和肝功能不全发生率,分析HBV再激活的影响因素。结果观察组患者HBV再激活率、肝功能不全总发生率分别为10.71%、19.64%,均低于对照组的28.57%、35.71%,差异均有统计学意义(P﹤0.05)。病理分期为Ⅲ~Ⅳ期及R-CHOP化疗方案是HBV再激活的危险因素(P﹤0.05),恩替卡韦是HBV再激活的保护因素(P﹤0.05)。结论 HBs Ag阴性NHL患者HBV再激活与多种因素相关,恩替卡韦可以减少NHL患者的HBV再激活率和肝功能不全总发生率。
Objective To analyze the related factors of hepatitis B virus（HBV） reactivation in hepatitis B surface antigen（HBs Ag） negative non-Hodgkin lymphoma（NHL） patients. Method One hundred and twelve NHL patients were chosen as study objects and divided into observation group and control group, each group had 56 cases. All patients were treated with CHOP or rituximab ＋ CHOP（R-CHOP） chemotherapy, and the patients in the observation group began oral entecavir 1 week before chemotherapy. The HBV reactivation rate and incidence of liver function injury were compared between two groups. The related factors of HBV reactivation were analyzed. Result In observation group, the reactivation rate and the incidence of liver function injury were 10.71% and 19.64%, which were significantly lower than those in control group as 28.57% and 35.71%, respectively（P〈0.05）. NHL stage Ⅲ-Ⅳ and R-CHOP were positively correlated with HBV reactivation（P〈0.05）, entecavir was negatively correlated with HBV reactivation（P〈0.05）. Conclusion HBV reactivation is associated with a variety of factors. Entecavir can significantly reduce the incidences of HBV reactivation and liver function injury.
作者
张丛丛
索晓慧
孙国锋
陈莉
赵燕莉
侯娟娟
ZHANG Congcong;SUO Xiaohui;SUN Guofeng;CHEN Li;ZHAO Yanli;HOU Juanjuan(Department of Hematology,Handan Central Hospital,Handan 056001,Hebei,China)
出处
《癌症进展》
2018年第7期905-907,共3页
Oncology Progress
